Prosecution Insights
Last updated: November 04, 2026
Application No. 18/950,156

DIPHENOLIC COMPOUNDS AND PREPARATION METHODS THEREOF

Non-Final OA §102§103§112
Filed
Nov 17, 2024
Priority
May 17, 2022 — CN 202210534437.8 +2 more
Examiner
LADD, CAROLYN LOUISE
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Purpana (Beijing) Technologies Co. Ltd.
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
51 granted / 87 resolved
-1.4% vs TC avg
Strong +47% interview lift
Without
With
+47.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
33 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
26.0%
-14.0% vs TC avg
§102
22.4%
-17.6% vs TC avg
§112
34.8%
-5.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 87 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Status of Claims Receipt is acknowledged of the Applicants’ Amendments and Remarks, filed July 15, 2026 which have been entered on the record. Claims 3-4, 6-7, and 9-14 are canceled. Claims 1-2, 5, 8, and 15-16 are amended. Claims 1-2, 5, 8, and 15-16 are pending and under consideration. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement Two information disclosure statements (IDS) submitted on February 12, 2025 and July 15, 2026 are acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Priority This application is a CON of PCT/CN2023/085442 filed March 31, 2023, which claims the benefit of priority to Chinese Patent Application No. CN202210534437.8, filed on May 17, 2022 and CN202211487425.0, filed November 24, 2022. Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d), and the certified copy has been filed. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Specification Abstract Objections Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. The abstract of the disclosure is objected to because the abstract is less than 50 words. A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The metes and bounds of claim 5 are rendered unclear by the phrase “wherein when R3, R4, R7 and R8 are not all H, n is 1, 2, or 3 and m is 1, 2 or 3,” because it is unclear how n and m are defined when R3, R4, R7, and R8 are all H. The lack of clarity renders the claims indefinite since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Therefore, claim 5 is rejected on grounds of indefiniteness. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry Number 80867-99-8 (Entered STN Registry on November 16, 1984, Information Disclosure Statement dated July 15, 2026, Non-Patent Literature No. 1). PNG media_image1.png 322 687 media_image1.png Greyscale Regarding claim 1, CAS Registry Number 80867-99-8 teaches the elements of claim 1 as detailed below. [AltContent: textbox (n = 1 R3 = R4 = HR1 = H)] PNG media_image2.png 134 203 media_image2.png Greyscale PNG media_image3.png 140 185 media_image3.png Greyscale Regarding claim 2, CAS Registry Number 80867-99-8 meets the limitations of claim 2, where R1 is H, R3 is H, R4 is H, and n is 1 as shown above. "A generic claim cannot be allowed to an applicant if the prior art discloses a species falling within the claimed genus." The species in that case will anticipate the genus. In re Slayter, 276 F.2d 408, 411, 125 USPQ 345, 347 (CCPA 1960); In re Gosteli, 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989). See MPEP § 2131.02, I. Therefore claims 1-2 are rejected as clearly anticipated by CAS Registry Number 80867-99-8. Claims 1-2 are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by CAS Registry Number 65422-05-1 (Entered STN Registry on November 16, 1984, Information Disclosure Statement dated July 15, 2026, Non-Patent Literature No. 1). PNG media_image4.png 377 695 media_image4.png Greyscale Regarding claim 1, CAS Registry Number 65422-05-1 teaches the elements of claim 1 as detailed below. [AltContent: textbox (n = 2 R3 = R4 = HR1 = H)] PNG media_image5.png 149 224 media_image5.png Greyscale PNG media_image3.png 140 185 media_image3.png Greyscale Regarding claim 2, CAS Registry Number 65422-05-1 meets the limitations of claim 2, where R1 is H, R3 is H, R4 is H, and n is 2 as shown above. "A generic claim cannot be allowed to an applicant if the prior art discloses a species falling within the claimed genus." The species in that case will anticipate the genus. In re Slayter, 276 F.2d 408, 411, 125 USPQ 345, 347 (CCPA 1960); In re Gosteli, 872 F.2d 1008, 10 USPQ2d 1614 (Fed. Cir. 1989). See MPEP § 2131.02, I. Therefore claims 1-2 are rejected as clearly anticipated by CAS Registry Number 65422-05-1. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non- obviousness. Claims 1-2 and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over CAS Registry Number 80867-99-8 (Entered STN Registry on November 16, 1984, Information Disclosure Statement dated July 15, 2026, Non-Patent Literature No. 1) in view of Lee et al. (Lee et al. 2021. Urolithin and reduced urolithin derivatives as potent inhibitors of tyrosinase and melanogenesis: importance of the 4-substituted resorcinol moiety. International Journal of Molecular Sciences, 22(11), p.5616). The teachings of CAS Registry Number 80867-99-8 are applied and set forth as taught above. CAS Registry Number 80867-99-8 does not teach cosmetic and pharmaceutical formulations of the compounds as claimed. Lee teaches that “Pharmacophore analyses showed that two hydroxyl groups of the 4-substituted resorcinol entity act as hydrogen bond donors in both mushroom and human tyrosinases… These results suggest that 2a is a promising candidate for the treatment of skin pigment disorders, and show the 4-substituted resorcinol entity importantly contributes to tyrosinase inhibition.” Lee further teaches that “Taken together, our studies of urolithin and o-phenylbenzyl alcohol derivatives indicate that the 4-substituted resorcinol is a mandatory backbone for potent tyrosinase inhibitory activity and that the type, position, and number of substituents on the phenyl ring markedly influence abilities to inhibit tyrosinase.” Therefore, Lee teaches the 4-substituted resorcinol core is key to pharmacological activity and additionally, that such compounds can be used to treat skin pigment disorders. Therefore, it would have been prima facie obvious before the effective filing date of the claimed invention to have utilized the compound in cosmetic and pharmaceutical formulations based the pharmacological activity associated with 4-substituted resorcinol as a pharmacophore and the well-known pharmacological and cosmetic applications of 4-substituted resorcinol analogues. Therefore, a person of ordinary skill in the arts would have been motivated to develop such cosmetic and pharmaceutical formulations as in claimed invention and consequently, would have arrived at the claimed invention with a reasonable expectation of success and as a highly predictable result. Therefore, Claims 1-2 and 15-16 are rejected as being obvious. Claims 1-2 and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over CAS Registry Number 65422-05-1 (Entered STN Registry on November 16, 1984, Information Disclosure Statement dated July 15, 2026, Non-Patent Literature No. 1) in view of Lee et al. (Lee et al. 2021. Urolithin and reduced urolithin derivatives as potent inhibitors of tyrosinase and melanogenesis: importance of the 4-substituted resorcinol moiety. International Journal of Molecular Sciences, 22(11), p.5616). The teachings of CAS Registry Number 65422-05-1 and Lee are applied and set forth as taught above. Similarly, as stated above, it would have been prima facie obvious before the effective filing date of the claimed invention to have utilized the compound in cosmetic and pharmaceutical formulations based the pharmacological activity associated with 4-substituted resorcinol as a pharmacophore and the well-known pharmacological and cosmetic applications of 4-substituted resorcinol analogues. Therefore, a person of ordinary skill in the arts would have been motivated to develop such cosmetic and pharmaceutical formulations as in claimed invention and consequently, would have arrived at the claimed invention with a reasonable expectation of success and as a highly predictable result. Therefore, Claims 1-2 and 15-16 are rejected as being obvious. Claims 5, 8, and 15-16 is rejected under 35 U.S.C. 103 as being unpatentable over CAS Registry Number 72132-81-1 (Entered STN Registry on November 16, 1984, Information Disclosure Statement dated July 15, 2026, Non-Patent Literature No. 1) in view of Sakai et al WO 01/19323 A1, Machine Translation, Information Disclosure Statement dated July 15, 2026, Foreign Patent No. 6). PNG media_image6.png 372 679 media_image6.png Greyscale Regarding claim 5, CAS Registry Number 72132-81-1 teaches the elements of claim 1 as detailed below excepting the limitation that not all substituents can be H. PNG media_image7.png 186 254 media_image7.png Greyscale PNG media_image8.png 190 268 media_image8.png Greyscale [AltContent: textbox (n = 2 R3 = R4 = HR1 = H)] Regarding claim 8, CAS Registry Number 72132-81-1 teaches compounds similar to those recited in claim 8 excepting R3 and R4 are H, not alkyl as shown below. PNG media_image9.png 172 363 media_image9.png Greyscale Sakai teaches compounds that are resorcinol analogues similar to instant invention, specifically compounds that show tyrosine activity and applications in cosmetics (abstract). Sakai teaches the importance of substitution at the 4-position, specifically that “Furthermore, it has been proposed to apply a specific compound having a 4-substituted resorcinol skeleton and a specific flavonoid compound to a whitening agent (Japanese Patent Application Laid-Open No. 2-49715, Japanese Patent Application Laid-Open No. 55-49). JP-A-11-411, JP-A-57-35506, JP-A-6-16531, etc.). Sakai teaches the following compound PNG media_image10.png 137 148 media_image10.png Greyscale , demonstrating where R3 is ethyl. Additionally, as per MPEP 2144.09 (II) “Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09 (II). Therefore, it would be prima facie obvious before the effective filing date of the claimed invention to modify CAS Registry Number 72132-81-1 to incorporate methyl and ethyl substituents as such substituents are generally of close structural similarity that such compounds would be expected to possess similar properties. Sakai additionally teaches similar resorcinol analogues including compounds with such ethyl substitution as instant invention that possess cosmetic and pharmaceutical properties in inhibiting tyrosinase activity. Consequently, a person of ordinary skill in the art would be motivated to modify CAS Registry Number 72132-81-1 based on the teachings of Sakai as part of standard structure-activity relationship studies in optimizing the cosmetic and/or pharmaceutical activity of such analogues and because such compounds are homologs. Therefore, one would arrive at the claimed invention with a reasonable expectation of success as a highly predictable result. It would be further prima facie obvious to use the compounds in pharmaceutical and cosmetic compositions as such an operation would be part of standard optimization as part of process optimization and development in the pharmaceutical and cosmetic arts and because Sakai teaches cosmetic and pharmaceutical applications of similar compounds. Therefore claims 1, 2, 5, 8, and 15-16 are rejected on grounds of obviousness. Conclusion Claims 1-2, 5, 8, and 15-16 are under consideration and are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CAROLYN L. LADD whose telephone number is (703)756-5313. The examiner can normally be reached M-Th, 7:00 am to 5:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H. Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.L./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Nov 17, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766150
SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS
3y 4m to grant Granted Oct 20, 2026
Patent 12758558
METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS
5y 0m to grant Granted Oct 13, 2026
Patent 12758565
METHODS OF TREATING P53 MUTANT CANCERS USING OGDH INHIBITORS
4y 8m to grant Granted Oct 13, 2026
Patent 12760014
SUCCINATE AND CRYSTAL FORM THEREOF AS THERAPEUTICS
3y 5m to grant Granted Oct 13, 2026
Patent 12759999
INDOLE CARBOXAMIDE COMPOUNDS
3y 7m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+47.1%)
3y 7m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 87 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month